These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

202 related articles for article (PubMed ID: 22617030)

  • 1. A transformation in the mechanism by which the urokinase receptor signals provides a selection advantage for estrogen receptor-expressing breast cancer cells in the absence of estrogen.
    Eastman BM; Jo M; Webb DL; Takimoto S; Gonias SL
    Cell Signal; 2012 Sep; 24(9):1847-55. PubMed ID: 22617030
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Crosstalk between the urokinase-type plasminogen activator receptor and EGF receptor variant III supports survival and growth of glioblastoma cells.
    Hu J; Jo M; Cavenee WK; Furnari F; VandenBerg SR; Gonias SL
    Proc Natl Acad Sci U S A; 2011 Sep; 108(38):15984-9. PubMed ID: 21896743
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Myosin light chain kinase functions downstream of Ras/ERK to promote migration of urokinase-type plasminogen activator-stimulated cells in an integrin-selective manner.
    Nguyen DH; Catling AD; Webb DJ; Sankovic M; Walker LA; Somlyo AV; Weber MJ; Gonias SL
    J Cell Biol; 1999 Jul; 146(1):149-64. PubMed ID: 10402467
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Dynamic assembly of the urokinase-type plasminogen activator signaling receptor complex determines the mitogenic activity of urokinase-type plasminogen activator.
    Jo M; Thomas KS; Marozkina N; Amin TJ; Silva CM; Parsons SJ; Gonias SL
    J Biol Chem; 2005 Apr; 280(17):17449-57. PubMed ID: 15728176
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Endogenously produced urokinase-type plasminogen activator is a major determinant of the basal level of activated ERK/MAP kinase and prevents apoptosis in MDA-MB-231 breast cancer cells.
    Ma Z; Webb DJ; Jo M; Gonias SL
    J Cell Sci; 2001 Sep; 114(Pt 18):3387-96. PubMed ID: 11591826
    [TBL] [Abstract][Full Text] [Related]  

  • 6. uPAR regulates pericellular proteolysis through a mechanism involving integrins and fMLF-receptors.
    Montuori N; Cosimato V; Rinaldi L; Rea VE; Alfano D; Ragno P
    Thromb Haemost; 2013 Feb; 109(2):309-18. PubMed ID: 23238745
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Neutralizing the EGF receptor in glioblastoma cells stimulates cell migration by activating uPAR-initiated cell signaling.
    Hu J; Muller KA; Furnari FB; Cavenee WK; VandenBerg SR; Gonias SL
    Oncogene; 2015 Jul; 34(31):4078-88. PubMed ID: 25347738
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A new class of orthosteric uPAR·uPA small-molecule antagonists are allosteric inhibitors of the uPAR·vitronectin interaction.
    Liu D; Zhou D; Wang B; Knabe WE; Meroueh SO
    ACS Chem Biol; 2015 Jun; 10(6):1521-34. PubMed ID: 25671694
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The urokinase receptor promotes cancer metastasis independently of urokinase-type plasminogen activator in mice.
    Jo M; Takimoto S; Montel V; Gonias SL
    Am J Pathol; 2009 Jul; 175(1):190-200. PubMed ID: 19497996
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Suppression of urokinase plasminogen activator receptor inhibits proliferation and migration of pancreatic adenocarcinoma cells via regulation of ERK/p38 signaling.
    Xue A; Xue M; Jackson C; Smith RC
    Int J Biochem Cell Biol; 2009; 41(8-9):1731-8. PubMed ID: 19433314
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Requirement of ERα and basal activities of EGFR and Src kinase in Cd-induced activation of MAPK/ERK pathway in human breast cancer MCF-7 cells.
    Song X; Wei Z; Shaikh ZA
    Toxicol Appl Pharmacol; 2015 Aug; 287(1):26-34. PubMed ID: 26006730
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Cell signaling by urokinase-type plasminogen activator receptor induces stem cell-like properties in breast cancer cells.
    Jo M; Eastman BM; Webb DL; Stoletov K; Klemke R; Gonias SL
    Cancer Res; 2010 Nov; 70(21):8948-58. PubMed ID: 20940399
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Epidermal growth factor receptor-dependent and -independent cell-signaling pathways originating from the urokinase receptor.
    Jo M; Thomas KS; O'Donnell DM; Gonias SL
    J Biol Chem; 2003 Jan; 278(3):1642-6. PubMed ID: 12426305
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Elevated urokinase-specific surface receptor expression is maintained through its interaction with urokinase plasminogen activator.
    Mahanivong C; Yu J; Huang S
    Mol Carcinog; 2007 Mar; 46(3):165-75. PubMed ID: 17186542
    [TBL] [Abstract][Full Text] [Related]  

  • 15. RNAi-mediated downregulation of uPAR synergizes with targeting of HER2 through the ERK pathway in breast cancer cells.
    Li C; Cao S; Liu Z; Ye X; Chen L; Meng S
    Int J Cancer; 2010 Oct; 127(7):1507-16. PubMed ID: 20063318
    [TBL] [Abstract][Full Text] [Related]  

  • 16. β-Catenin and NF-κB cooperate to regulate the uPA/uPAR system in cancer cells.
    Moreau M; Mourah S; Dosquet C
    Int J Cancer; 2011 Mar; 128(6):1280-92. PubMed ID: 20473943
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The urokinase-system in tumor tissue stroma of the breast and breast cancer cell invasion.
    Hildenbrand R; Schaaf A
    Int J Oncol; 2009 Jan; 34(1):15-23. PubMed ID: 19082473
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Integrin-uPAR signaling leads to FRA-1 phosphorylation and enhanced breast cancer invasion.
    Annis MG; Ouellet V; Rennhack JP; L'Esperance S; Rancourt C; Mes-Masson AM; Andrechek ER; Siegel PM
    Breast Cancer Res; 2018 Jan; 20(1):9. PubMed ID: 29382358
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Expression of urokinase-type plasminogen activator (uPA), its receptor (uPAR), and inhibitor (PAI-1) in human breast carcinomas and their clinical relevance.
    Andres SA; Edwards AB; Wittliff JL
    J Clin Lab Anal; 2012 Feb; 26(2):93-103. PubMed ID: 22467324
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Interleukin-1alpha enhances the aggressive behavior of pancreatic cancer cells by regulating the alpha6beta1-integrin and urokinase plasminogen activator receptor expression.
    Sawai H; Okada Y; Funahashi H; Matsuo Y; Takahashi H; Takeyama H; Manabe T
    BMC Cell Biol; 2006 Feb; 7():8. PubMed ID: 16504015
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.